Singapore, Aug. 27 -- Abbott, the global healthcare leader, has received regulatory approval for the firstdenosumab biosimilar in Thailand, expanding access to advanced therapies for osteoporosis and cancer-related bone loss.

With the introduction of Abbott's denosumab biosimilar in Thailand, this advanced biologic treatment will be more affordable and accessible for the estimated 3 million people suffering from osteoporosis and bone-disease related illness in the country.

Osteoporosis, a chronic and age-related disease, isa serious public health concern. The condition has a significant and often debilitating impact, including fractures that lead to loss of independence and reduced quality of life.In Thailand, 1 in 5 women and 1 in 10 m...